hemotune raises CHF 14 million Series B2 funding for clinical trials with the HemoSystem
Schlieren, Switzerland, March 25th, 2024 – hemotune AG, a pioneering Swiss biotech company, today announced the successful closing of a CHF 14 million Series B2 round dedicated to advancing its HemoSystem, a breakthrough blood purification platform based on nanoengineered magnetic beads. The investment was led by Belmondo with continued support of existing investors including VP Venture Partners, HEMEX, OCCIDENT, Zürcher Kantonalbank, and joined by EFI.
The Series B2 funding round represents a significant step forward for hemotune, following the successful completion of preclinical development for their HemoSystem blood purification platform. This substantial investment will now allow the platform to move into clinical trials, marking a crucial phase in its development.
The HemoSystem stands out for its ability to effectively remove large biomolecules directly from patients’ bloodstreams, offering a unique approach to implement precision medicine multi-target treatments which would not be possible through drugs. Initially focusing on treating sepsis-related immune suppression, hemotune also plans to explore other potential uses for the platform in the future. Given the serious impact of sepsis, which leads to around 11 million deaths annually and is a major economic burden, the potential benefits of this innovative technology are significant for patients and healthcare systems alike.
Lukas Langenegger, CEO and co-founder of hemotune AG, states: “I am immensely proud of our team’s achievements in concluding the preclinical development of the HemoSystem. As we navigate through a challenging fundraising climate, the success of our Series B2 funding round underscores not only the potential of our innovative blood purification platform but also the confidence our backers have in our team and vision to revolutionize medical treatment.”
Dr. Darius Madjdpour, founder at Belmondo comments: “The team of hemotune, through an impressive performance over the last 7 years, has managed to develop one of the most promising platform technologies I have seen in medicine. The possibilities to tackle various diseases and enabling therapies through HemoSystem has convinced us to take the lead in this funding round. We are happy to support the team for further journey and will be excited to see the product spread globally and help many patients over the coming years.”
Cédric Barra, Senior Investment Manager at OCCIDENT: “This Series B2 funding will now pave the way for clinical trials. The company has done an excellent job over the last few years to get to this point and we hope that hemotune can make the therapy available to patients soon.”
Dr. Annick Bay, Senior Associate of VP Venture Partners adds: ”hemotune’s precision blood purification system is designed to specifically remove individual proteins or combinations thereof, resulting in a medical device platform more akin to therapeutics developed by a traditional biotech, with the added benefit of a leaner development pathway for individual indications.”
Pascal Winnen, CEO of HEMEX, asserts: “With our established expertise as a CRO in managing global infectious disease clinical trials, we are deeply committed to hemotune’s pioneering strategy for combating septic shock. We recognize the potential for broader applications of their technology to selectively filter harmful agents from the bloodstream. Our team is eager to provide robust support to hemotune throughout the clinical phase of their development program. Our ultimate aim is to facilitate the worldwide availability of the innovative HemoSystem for patients in need.”